Stockscreener 앱 받기
39.15
0.20%
0.08
전일 마감가:
$39.07
열려 있는:
$38.73
하루 거래량:
2.47M
Relative Volume:
0.77
시가총액:
$10.54B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
22.12
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+3.35%
1개월 성능:
+3.16%
6개월 성능:
+5.24%
1년 성능:
+48.80%
1일 변동 폭
$38.59
$39.27
1주일 범위
$36.78
$39.27
52주 변동 폭
$25.17
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
39.15 | 10.15B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis Announces New Executive VP for R&D - MSN
market reaction to exelixis inc.’s recent newsMarket Performance Report & Weekly Breakout Opportunity Watchlist - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
Exelixis at H.C. Wainwright: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-10-2025 08 - MarketScreener
Kestra Investment Management LLC Has $744,000 Position in Exelixis, Inc. $EXEL - MarketBeat
AlphaQuest LLC Sells 14,154 Shares of Exelixis, Inc. $EXEL - MarketBeat
New Vernon Capital Holdings II LLC Takes $8.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
NFJ Investment Group LLC Raises Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Morgan Stanley Conference: Oncology Growth and Strategic Focus - Investing.com
Exelixis, Inc. $EXEL Shares Purchased by Royal Bank of Canada - MarketBeat
Moving Average Crossover Confirms Uptrend in Exelixis Inc.2025 Growth vs Value & Low Drawdown Investment Strategies - beatles.ru
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis Inc. Recovery Likely Here’s What Data ShowsWeekly Trading Summary & Free Real-Time Volume Trigger Notifications - beatles.ru
Will Exelixis Inc. Hold Gains Into CloseMarket Growth Review & Daily Growth Stock Investment Tips - beatles.ru
Jacobs Levy Equity Management Inc. Sells 90,427 Shares of Exelixis, Inc. $EXEL - MarketBeat
What’s Exelixis Inc.’s historical return2025 Volatility Report & Stock Timing and Entry Methods - beatles.ru
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
Analyzing Exelixis Inc. with risk reward ratio chartsRisk Management & Precise Buy Zone Tips - Newser
Is Exelixis Inc. building a consolidation baseWeekly Trend Report & Smart Swing Trading Alerts - Newser
Will Exelixis Inc. be affected by tariffs2025 Stock Rankings & Real-Time Market Sentiment Reports - خودرو بانک
Can Exelixis Inc. lead its sector in growth2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What drives Exelixis Inc.’s stock priceSwing Trade & Growth Focused Stock Pick Reports - خودرو بانک
Trexquant Investment LP Cuts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL): A Bull Case Theory - MSN
Can Exelixis Inc. be recession proofDividend Hike & Daily Growth Stock Investment Tips - خودرو بانک
Exelixis, Inc. (EXEL): A High-Conviction Biotech Play with Cash-Generative Momentum and a De-Risked Pipeline - AInvest
Using data models to predict Exelixis Inc. stock movementEarnings Miss & Weekly Watchlist of Top Performers - Newser
Ranking Exelixis Inc. among high performing stocks via tools2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Exelixis Inc.’s growth already priced inJuly 2025 Snapshot & Weekly Top Gainers Trade List - خودرو بانک
What candlestick patterns are forming on Exelixis Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Price momentum metrics for Exelixis Inc. explained2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Live market analysis of Exelixis Inc.2025 Analyst Calls & Growth Focused Entry Reports - Newser
Will Exelixis Inc. benefit from AI trendsRecession Risk & Precise Trade Entry Recommendations - خودرو بانک
Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves - Endpoints News
Institutional scanner results for Exelixis Inc.Weekly Stock Analysis & Short-Term Trading Alerts - Newser
Will Breakout in Exelixis Inc. Sustain Through Next WeekMarket Performance Report & Low Risk Entry Point Guides - 더경남뉴스
Is Exelixis Inc. backed by strong institutional buyingJuly 2025 Review & Safe Capital Growth Tips - خودرو بانک
Statistical indicators supporting Exelixis Inc.’s strengthWeekly Profit Summary & Daily Risk Controlled Trade Plans - Newser
Intraday pattern recognizer results for Exelixis Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - Newser
Exelixis Cuts 130 Jobs as Company Shuts Down Pennsylvania Facility - AInvest
Exelixis Investigated for Misleading Statements, Shares Fall 16.8% - AInvest
Exelixis shuttering Pennsylvania site, laying off 130 employees - Seeking Alpha
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Exelixis at Citi’s Biopharma Conference: Strategic Growth and Innovation - Investing.com
Is Exelixis Inc. stock bottoming outPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):